Detalhe da pesquisa
1.
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
Blood
; 138(24): 2499-2513, 2021 12 16.
Artigo
Inglês
| MEDLINE | ID: mdl-34166502
2.
Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL.
Blood
; 140(20): 2175-2179, 2022 11 17.
Artigo
Inglês
| MEDLINE | ID: mdl-35776908
3.
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use.
Hemasphere
; 7(8): e907, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-37449196
4.
Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL.
Hemasphere
; 7(4): e858, 2023 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-37038465
5.
Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL.
Blood Adv
; 7(22): 6844-6849, 2023 11 28.
Artigo
Inglês
| MEDLINE | ID: mdl-37748131